AU2017223838B2 - Treatment of neurodegenerative eye disease using pridopidine - Google Patents

Treatment of neurodegenerative eye disease using pridopidine Download PDF

Info

Publication number
AU2017223838B2
AU2017223838B2 AU2017223838A AU2017223838A AU2017223838B2 AU 2017223838 B2 AU2017223838 B2 AU 2017223838B2 AU 2017223838 A AU2017223838 A AU 2017223838A AU 2017223838 A AU2017223838 A AU 2017223838A AU 2017223838 B2 AU2017223838 B2 AU 2017223838B2
Authority
AU
Australia
Prior art keywords
pridopidine
subject
eye
administration
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017223838A
Other languages
English (en)
Other versions
AU2017223838A1 (en
Inventor
Michal Geva
Ralph Laufer
Aric ORBACH
Hermann Kurt Russ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prilenia Neurotherapeutics Ltd
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of AU2017223838A1 publication Critical patent/AU2017223838A1/en
Assigned to PRILENIA THERAPEUTICS DEVELOPMENT LTD. reassignment PRILENIA THERAPEUTICS DEVELOPMENT LTD. Request for Assignment Assignors: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Assigned to PRILENIA NEUROTHERAPEUTICS LTD. reassignment PRILENIA NEUROTHERAPEUTICS LTD. Amend patent request/document other than specification (104) Assignors: PRILENIA THERAPEUTICS DEVELOPMENT LTD.
Application granted granted Critical
Publication of AU2017223838B2 publication Critical patent/AU2017223838B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017223838A 2016-02-24 2017-02-24 Treatment of neurodegenerative eye disease using pridopidine Active AU2017223838B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662299290P 2016-02-24 2016-02-24
US62/299,290 2016-02-24
PCT/US2017/019266 WO2017147366A1 (en) 2016-02-24 2017-02-24 Treatment of neurodegenerative eye disease using pridopidine

Publications (2)

Publication Number Publication Date
AU2017223838A1 AU2017223838A1 (en) 2018-09-06
AU2017223838B2 true AU2017223838B2 (en) 2022-09-29

Family

ID=59686581

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017223838A Active AU2017223838B2 (en) 2016-02-24 2017-02-24 Treatment of neurodegenerative eye disease using pridopidine

Country Status (10)

Country Link
US (1) US11738012B2 (https=)
EP (1) EP3419622B1 (https=)
JP (1) JP7034488B2 (https=)
AU (1) AU2017223838B2 (https=)
CA (1) CA3015512C (https=)
DK (1) DK3419622T3 (https=)
ES (1) ES2979123T3 (https=)
HU (1) HUE066769T2 (https=)
PL (1) PL3419622T3 (https=)
WO (1) WO2017147366A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US20220062255A1 (en) * 2016-02-24 2022-03-03 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
ES3025836T3 (en) 2016-08-24 2025-06-09 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating functional decline
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
AU2018329628B2 (en) 2017-09-08 2021-04-22 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3920924A4 (en) 2019-02-04 2022-11-16 Prilenia Neurotherapeutics Ltd. LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES
CN113597310A (zh) * 2019-03-15 2021-11-02 普瑞尼亚神经治疗有限公司 使用普利多匹定治疗线粒体相关疾病和病症，包含其症状
EP4415714A4 (en) * 2021-10-11 2025-10-15 Prilenia Neurotherapeutics Ltd PRIDOPIDINE AND ANALOGUES THEREOF FOR THE TREATMENT OF NEURODEGENERATIVE EYE DISEASE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
IL134241A (en) * 2000-01-27 2006-06-11 Finetech Pharmaceutical Ltd Process for the preparation of latanoprost
WO2004103263A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
SI2146961T1 (sl) 2007-04-12 2014-08-29 IVAX International GmbH N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov
EP2170343A1 (en) 2007-05-31 2010-04-07 Joseph Weinstock Treatment of age-related macular degeneration
CA2698695A1 (en) 2007-09-05 2009-03-12 Teva Pharmaceutical Industries Ltd. Method of treating glaucoma using rasagiline
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CN103958469B (zh) 2011-09-07 2016-04-20 梯瓦制药国际有限责任公司 一种新的普利多匹定盐酸盐多晶型形态
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
HK1206297A1 (en) 2012-04-04 2016-01-08 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
EP2900226A4 (en) 2012-09-27 2016-03-30 Teva Pharma COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
PE20160195A1 (es) 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
PE20161220A1 (es) 2014-01-22 2016-11-23 Teva Pharmaceuticals Int Gmbh Formulaciones de pridopidina de liberacion modificada
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
CA2993183A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
KR20200031446A (ko) 2018-09-14 2020-03-24 삼성전자주식회사 무선 통신 시스템에서 pdcch 모니터링 방법 및 장치

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Mueller, B (2014) 'Neuroprotective properties of sigma-1 receptor in glaucoma' [obtained from internet on 03 November 2021] <URL: http://digitalcommons.hsc.unt.edu/cgi/viewcontent.cgi?article=1758&context=theses> *
Sahlholm, K et al (2015) "Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses." Psychopharmacology 232(18): 3443-53. doi:10.1007/s00213-015-3997-8 *

Also Published As

Publication number Publication date
JP2019507758A (ja) 2019-03-22
EP3419622A4 (en) 2019-07-10
ES2979123T3 (es) 2024-09-24
PL3419622T3 (pl) 2024-07-08
CA3015512C (en) 2024-01-16
DK3419622T3 (da) 2024-06-03
AU2017223838A1 (en) 2018-09-06
EP3419622A1 (en) 2019-01-02
JP7034488B2 (ja) 2022-03-14
US11738012B2 (en) 2023-08-29
US20190046516A1 (en) 2019-02-14
EP3419622B1 (en) 2024-03-06
HUE066769T2 (hu) 2024-09-28
CA3015512A1 (en) 2017-08-31
WO2017147366A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
AU2017223838B2 (en) Treatment of neurodegenerative eye disease using pridopidine
EP3886858B1 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
JP2019518730A (ja) 眼の炎症性障害および疾患の組合せ処置
US11654140B2 (en) Treatment of ocular inflammatory diseases using laquinimod
US20180140593A1 (en) Treatment of Glaucoma Using Laquinimod
Al-Namaeh Systemic medications and their ocular side effects
US20240261273A1 (en) Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease
US20220062255A1 (en) Treatment of neurodegenerative eye disease using pridopidine
RU2805061C2 (ru) Лечение демиелинизирующих заболеваний
Mashael Systemic Medications and Their Ocular Side Effects
AU2025217391A1 (en) Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease
HK40061312B (en) Compounds for treatment of eye diseases associated with excessive vascularisation
JP2024032794A (ja) 網膜の神経細胞の保護剤

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: PRILENIA THERAPEUTICS DEVELOPMENT LTD.

Free format text: FORMER APPLICANT(S): TEVA PHARMACEUTICALS INTERNATIONAL GMBH

HB Alteration of name in register

Owner name: PRILENIA NEUROTHERAPEUTICS LTD.

Free format text: FORMER NAME(S): PRILENIA THERAPEUTICS DEVELOPMENT LTD.

FGA Letters patent sealed or granted (standard patent)